Novel Therapeutics
The commonly used drug to treat Parkinson’s disease is Levodopa which has higher frequency to develop motor Fluctuations and results in L-dopa-induced dyskinesia (LID). Since the Characteristic key cause of Parkinson’s disease is reduced production level dopamine by neurons, research studies developed a molecule called LXR (Liver X Receptor) where it has got potential to reduce the loss of dopaminergic neurons. Researchers propose novel ideas to treat Parkinson’s disease to reduce the risk of causing side effects, frequency of dyskinesia, to treat cognitive disorders such as anxiety and depression.
- Repetitive Transcranial Magnetic Stimulation
- NMDA Receptor for Cognitive Dysfunction
Related Conference of Novel Therapeutics
June 22-23, 2026
18th Global Neurologists Meeting on Neurology and Neurosurgery
Amsterdam, Netherlands
June 29-30, 2026
31st International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences
Paris, France
July 20-21, 2026
11th International Conference on Central Nervous System Disorders & Therapeutics
Amsterdam, Netherlands
July 23-24, 2026
14th International Conference on Cannabis & Medicinal Research
Amsterdam, Netherlands
September 17-18, 2026
31st Global Experts Meeting on Neuroscience and Neuropharmacology
Paris, France
April 27-28, 2027
18th International Conference on Stroke, Neurology and Cerebrovascular Diseases
Paris, France